Advertisement

American Journal of Clinical Dermatology

, Volume 4, Issue 4, pp 235–243 | Cite as

Hypertrophic Scars and Keloids

Etiology and Management
  • Tina S. AlsterEmail author
  • Elizabeth L. Tanzi
Therapy In Practice

Abstract

Keloid and hypertrophic scars have affected patients and frustrated physicians for centuries. Keloid and hypertrophic scars result from excessive collagen deposition, the cause of which remains elusive. Clinically, these scars can be disfiguring functionally, aesthetically, or both. A thorough understanding of the pathophysiology and clinical nature of the scar can help define the most appropriate treatment strategy.

Although many articles have been published on the management of hypertrophic and keloid scars, there is no universally accepted treatment protocol. Prevention of keloid and hypertrophic scars remains the best strategy; therefore, those patients with a predisposition to develop excessive scar formation should avoid nonessential surgery. Once a scar is present, there are many treatments from which to choose. Hypertrophic scars and keloids have been shown to respond to radiation, pressure therapy, cryotherapy, intralesional injections of corticosteroid, interferon and fluorouracil, topical silicone or other dressings, and pulsed-dye laser treatment. Simple surgical excision is usually followed by recurrence unless adjunct therapies are employed. Biologic agents that are directed towards the aberrant collagen proliferation that characterizes keloid and hypertrophic scars might be an important addition to the current armamentarium of modalities in the near future.

Keywords

Hyaluronic Acid Imiquimod Hypertrophic Scar Triamcinolone Acetonide Pressure Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Breasted HG. The Edwin Smith surgical papyrus: hieroglyphic translation and commentary. Chicago: University of Chicago Press, 1930Google Scholar
  2. 2.
    Alibert JLM. Quelques recherches sur la cheloide. Mem Soc Medicale d’Emulation 1917; 8: 744–752Google Scholar
  3. 3.
    Urioste SS, Arndt KA, Dover JS. Keloidal scars and hypertrophic scars: review and treatment strategies. Semin Cutan Med Surg 1999; 18: 159–171PubMedCrossRefGoogle Scholar
  4. 4.
    Muir IFK. On the nature of keloidal scars and hypertrophic scars. Br J Plast Surg 1990; 43: 61–69PubMedCrossRefGoogle Scholar
  5. 5.
    Niessen FE, Spauwen PH, Schalkwijk J, et al. On the nature of hypertrophic scars and keloidal scars: a review. Plast Reconstr Surg 1999; 105: 1435–1458Google Scholar
  6. 6.
    Datubo-Brown DD. Keloids: a review of the literature. Br J Plast Surg 1990; 43: 276–280Google Scholar
  7. 7.
    Cosman B, Crikelair GF, Ju MC, et al. The surgical treatment of keloidal scars. Plast Reconstr Surg 1961; 27: 335–358CrossRefGoogle Scholar
  8. 8.
    Larrabee Jr WF, East CA, Jaffe HS, et al. Intralesional interferon gamma treatment for keloidal scars and hypertrophic scars. Arch Otolaryngol Head Neck Surg 1990; 116: 1159–1162PubMedCrossRefGoogle Scholar
  9. 9.
    Pollack SV, Goslen JB. The surgical treatment of keloidal scars. J Dermatol Surg Oncol 1982; 8: 1045–1049PubMedGoogle Scholar
  10. 10.
    English RS, Shenefelt PD. Keloids and hypertrophic scars. Dermatol Surg 1999; 25: 631–638PubMedCrossRefGoogle Scholar
  11. 11.
    Murray J. Scars and keloids. Dermatol Clin 1993; 11: 697–708PubMedGoogle Scholar
  12. 12.
    Stegman SL, Tromovitch TA, Glogan RG. Treatment of keloids. In: Stegman SJ, editor. Cosmetic dermatologic surgery. 2nd ed. Chicago: Year Book Medical, 1990: 201–206Google Scholar
  13. 13.
    Stocker FJ, Shaw Gy. An approach to management of keloids. Arch Otolaryngol Head Neck Surg 1992; 118: 63–67CrossRefGoogle Scholar
  14. 14.
    Ketchum LD, Cohen IK, Masters FW. Hypertrophic scars and keloids. Plast Reconstr Surg 1974; 53: 140–153PubMedCrossRefGoogle Scholar
  15. 15.
    Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46: S63–S97PubMedCrossRefGoogle Scholar
  16. 16.
    Matas R. The surgical peculiarities of the Negro. Tr Am Surg A 1896; 14: 483–485Google Scholar
  17. 17.
    Abrams BJ, Benedetto AV, Humeniuk HM. Exuberant keloidal formation. J Am Osteopath Assoc 1993; 93: 863–865PubMedGoogle Scholar
  18. 18.
    Rockwell WE, Cohen IK, Ehrilich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg 1989; 84: 827–837PubMedCrossRefGoogle Scholar
  19. 19.
    Alhady SM, Sivanantharajah K. Keloids in various races: a review of 175 cases. Plast Reconstr Surg 1969; 44: 564–566PubMedCrossRefGoogle Scholar
  20. 20.
    Mathangi-Ramakrishnan K, Pothan-Thomas K, Cheyyur R. Study of 1000 patients with keloidal scars in south India. Plast Reconstr Surg 1974; 53: 276–280CrossRefGoogle Scholar
  21. 21.
    Davies DM. Scars, hypertrophic scars and keloids. Plast Reconstr Surg 1985; 290: 1056–1058Google Scholar
  22. 22.
    Marneros AG, Norris IE, Olsen BR, et al. Clinical genetics of familial keloids. Arch Dermatol 2001; 137: 1429–1434PubMedGoogle Scholar
  23. 23.
    Crockett DJ, Regional keloid susceptibility. Br J Plast Surg 1964; 17: 245–253PubMedCrossRefGoogle Scholar
  24. 24.
    Fong EP, Chye LT, Tan WL. Keloids: time to dispel the myths? Plast Reconstr Surg 1999; 104: 1199–1201PubMedGoogle Scholar
  25. 25.
    Sherris DA, Larrabee WF, Murakami CS. Management of scar contractures, hypertophic scars and keloidal scars. Otolaryngol Clin North Am 1995; 28: 1057–1068PubMedGoogle Scholar
  26. 26.
    Kazeem AA. The immunological aspects of keloid tumor formation. J Surg Oncol 1988; 38: 16–18PubMedCrossRefGoogle Scholar
  27. 27.
    Ehrlich HP, Desmouliere A, Diegelmann RF, et al. Morphological and immunochemical differeoces between keloid and hypertrophic scars. Am J Pathol 1994; 145: 105–113PubMedGoogle Scholar
  28. 28.
    Alster TS, West lB. Treatment of scars: a review. Ann Plast Surg 1997; 39: 418–432PubMedCrossRefGoogle Scholar
  29. 29.
    Abergel RP, Pizzurro D, Meeker CA, et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J Invest Dermatol 1985; 84: 384–390PubMedCrossRefGoogle Scholar
  30. 30.
    Russell SR, Trupin JS, Kennedy RZ, et al. Glococorticoid regulation of elastin synthesis in human fibroblasts: down regulation in fibroblasts from normal dermis but not from keloids. J Invest Dermatol 1995; 105: 241–245CrossRefGoogle Scholar
  31. 31.
    Babu M, Diegelmann R, Oliver N. Fibronectin is overproduced by keloid fibroblasts during abnormal wound healing. Mol Cell Biol 1989; 9: 1642–1650PubMedGoogle Scholar
  32. 32.
    Kischer CW, Hendrix MJ. Fibronectin in hypertrophic scars and keloids. Cell Tissue Res 1983; 231: 29–37PubMedGoogle Scholar
  33. 33.
    McCoy BJ, Cohen IK. Effects of various sera on growth kinetics and collagen synthesis by keloid and normal dermal fibroblasts. Plast Reconstr Surg 1981; 67: 505–510PubMedCrossRefGoogle Scholar
  34. 34.
    Bettinger DA, Yager DR, Diegelmann RF, et al. The effects of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 1996; 98: 827–833PubMedCrossRefGoogle Scholar
  35. 35.
    Calderon M, Lawreoce WT, Banes AJ. Increased proliferation of keloid fibroblasts in vitro. J Surg Res 1996; 61: 343–347PubMedCrossRefGoogle Scholar
  36. 36.
    Younai S, Nichter is, Wellisz T, et al. Modulation of collagen synthesis by transforming growth factor beta in keloid and hypertrophic scar fibroblasts. Ann Plast Surg 1994; 33: 148–151PubMedCrossRefGoogle Scholar
  37. 37.
    Luo S, Benathan M, Raffoul W, et al. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg 2001; 107: 87–96PubMedCrossRefGoogle Scholar
  38. 38.
    Akasaka Y, Fujita K, Ishikawa Y, et al. Detection of apoptosis in keloids and a comparative study on apoptosis between keloids, hypertrophic scars, normal healed flat scars, and dermatofibroma. Wound Repair Regen 2001; 9: 501–506PubMedCrossRefGoogle Scholar
  39. 39.
    Peltonen J, Hsiao LL, Jaakola S, et al. Activation of collagen gene expression in keloids: co-localization of type I and VI collagen and transforming growth factor beta 1 mRNA. J Invest Dermatol 1992; 99: 650–655CrossRefGoogle Scholar
  40. 40.
    Smith P, Mosiello G, Deloca L, et al. TGF-beta2 activates proliferative scar fibroblasts. J Surg Res 1999; 82: 319–323PubMedCrossRefGoogle Scholar
  41. 41.
    Wang X, Smith P, Po LLQ, et al. Exogenous transforming growth factor beta2 modulates collagen I and collagen III synthesis in proliferative scar xenografts in nude rats. J Surg Res 1999; 87: 194–200PubMedCrossRefGoogle Scholar
  42. 42.
    Ghahary A, Shen YJ, Nedelec B, et al. Enhanced expression of mRNA for insulin-like growth factor-1 in post burn hypertrophic scar tissue and its fibrogenic role by dermal fibroblasts. Mol Cell Biochem 1995; 148: 25–32PubMedCrossRefGoogle Scholar
  43. 43.
    Yoshimoto H, Hiroshi I, Ohtsuru A, et al. Overexpression of insulin-like growth factor-1 (IGF-1) reeeptor and the invasiveness of cultured keloid fibroblasts. Am J Pathol 1999; 154: 883–889PubMedCrossRefGoogle Scholar
  44. 44.
    Xue H, McCauley RL, Zhang W. Elevated interleukin-6 expression in keloid fibroblasts. J Surg Res 2000; 89: 74–77PubMedCrossRefGoogle Scholar
  45. 45.
    Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000; 292: 988–994PubMedGoogle Scholar
  46. 46.
    Castagnoli C, Trombotto C, Ariotti S, et al. Expression and role of IL-15 in postburn hypertrophic scars. J Invest Dermatol 1999; 113: 238–245PubMedCrossRefGoogle Scholar
  47. 47.
    Alaish SM, Yager DR. Diegelmann RF, etal. Hyaluronic acid metabolism in keloid fibroblasts. J Pediatr Surg 1995; 30: 949–952PubMedCrossRefGoogle Scholar
  48. 48.
    Bertheim U, Hellstrom S. The distribution of hyaluronan in human skin and mature,hypertrophic and keloid scars. Br J Plast Surg 1994; 47: 483–489PubMedCrossRefGoogle Scholar
  49. 49.
    Castagnoli C, Stella M, Magliacani G, et al. Anomalous expression of HLA class II molecules on keratinocytes and fibroblasts in hypertrophic scars consequent to thermal injury. Clin Exp Immunol 1990; 82: 350–354PubMedCrossRefGoogle Scholar
  50. 50.
    Castagnoli C, Perruccio D, Stella M, et al. The HLA-DR beta 16 allogenotype constitutes a risk factor for hypertrophic scarring. Hum Immunol 1990; 29: 229–232PubMedCrossRefGoogle Scholar
  51. 51.
    Cohen IK, McCoy BJ, Mohanakumar T, et al. Immunoglobulin, complement and histocompatibility antigen studies in keloid patients. Plast Reconstr Surg 1979; 63: 689–695PubMedCrossRefGoogle Scholar
  52. 52.
    Kischer CW, Shetlar MR, Shetlar CL, et al. Immunoglobulins in hypertrophic scars and keloids. Plast Reconstr Surg 1983; 71: 821–825PubMedCrossRefGoogle Scholar
  53. 53.
    Bloch EF, Hall MG, Denson MJ, et al. General immune reactivity in keloid patients. Plast Reconstr Surg 1984; 73: 448–451PubMedCrossRefGoogle Scholar
  54. 54.
    Boyce DE, Ciarrpolini J, Ruge F, et al. Inflammatory cell populations in keloid scars. Br J Plast Surg 2001; 54: 511–516PubMedCrossRefGoogle Scholar
  55. 55.
    Bernabei P, Rigamonti L, Ariotti S, et al. Fuoctional analysis of T lymphocytes infiltrating the dermis and epidermis of post-burn hypertrophic scar tissues. Burns 1999; 25: 43–48PubMedCrossRefGoogle Scholar
  56. 56.
    Kischer CW, Thies AC, Chvapil M. Perivascular myofibroblasts and microvascular occlusion in hypertrophic scars and keloids. Hum Pathal 1982; 13: 819–824CrossRefGoogle Scholar
  57. 57.
    Louw L, Engelbrecht AM, Cloete F, et al. Impairment in the fatty acid composition of keloidal scars. In: Ronn KV, Nigam S, Marnett LJ, editors. Eicosanoids and other bioactive lipids in cancer inflammation and radiation injury 2. Chapter 116. New York: Plenum Press, 1997: 905–910Google Scholar
  58. 58.
    Cobbold CA, Sherratt JA. Mathematical modeling of nitric oxide activity in wound healing can explain keloid and hypertrophic scarring. J Theor Biol 2000; 204: 257–288PubMedCrossRefGoogle Scholar
  59. 59.
    Yagi K, Dafalla AA, Osman AA. Does an immune reaction to sebum in wounds cause keloid scars?.: beneficial effect of desensitization. Br J Plast Surg 1979; 32: 223–227PubMedGoogle Scholar
  60. 60.
    Cosman B, Wolff M. Correlation of keloid recurrence with completeness of local excision: a negative report. Plast Reconstr Surg 1972; 50: 163–166PubMedCrossRefGoogle Scholar
  61. 61.
    Lawrence WT. In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann Plast Surg 1991; 27: 164–178PubMedCrossRefGoogle Scholar
  62. 62.
    Kovalic JJ, Perez CA. Radiation therapy following keloidectomy: a 20-year experience. Int J Radiat Oncol Biol Phys 1989; 17: 77–80PubMedCrossRefGoogle Scholar
  63. 63.
    Lee Y, Minn KW, Baek RM, et al. A new surgical treatment of keloid: keloid core excision. Ann Plast Surg 2001; 46: 135–140PubMedCrossRefGoogle Scholar
  64. 64.
    Sclafani AP, Gordon L, Chadha M, et al. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy. Dermatol Surg 1996; 22: 569–574PubMedCrossRefGoogle Scholar
  65. 65.
    Ragoowansi R, Cornes PGS, Glees JP, et al. Ear-lobe keloids: treatment by a protocol of surgical excision and immediate postoperative adjuvant radiotherapy. Br J Plast Surg 2001; 54: 504–508PubMedCrossRefGoogle Scholar
  66. 66.
    Doormos JF, Stoffel TJ, Hass AC, et al. The role of kilovoltage irradiation in the treatment of keloids. Int J Radiat Oncol Biol Phys 1990; 18: 833–839CrossRefGoogle Scholar
  67. 67.
    Ship AG, Weiss PR, Mincer FR, et al. Sternal keloids: successful treatment employing surgery and adjuvant radiation. Ann Plast Surg 1993; 31: 481–487PubMedCrossRefGoogle Scholar
  68. 68.
    Botwood N, Lewanski C, Lowdell C. The risks of treating keloids with radiotherapy. Br J Radiol 1999; 72: 1222–1224PubMedGoogle Scholar
  69. 69.
    Cronin TD. The use of a molded splint to prevent contracture after split skin grafting on the neck [letter]. Plast Reconstr Surg 1961; 27: 7CrossRefGoogle Scholar
  70. 70.
    Bauer PS, Larson DL, Stacey TR, et al. Ultrastructural analysis of pressure treated human hypertrophic scars. J Trauma 1976; 16: 958–967CrossRefGoogle Scholar
  71. 71.
    Brent B. The role of pressure therapy in management of earlobe keloids: preliminary report of a controlled study. Ann Plast Surg 1978; 1: 579–581PubMedCrossRefGoogle Scholar
  72. 72.
    Russell R, Horlock N, Gault D. Zimmer splintage: a simple effective treatment for keloids following ear-piercing. Br J Plast Surg 2001; 54: 509–510PubMedCrossRefGoogle Scholar
  73. 73.
    Reno F, Grazianetti P, Stella M, et al. Release and activation of matrix metalloproteinase-9 during in vitro mechanical compression in hypertrophic scars. Arch Dermatol 2002; 138: 475–478PubMedCrossRefGoogle Scholar
  74. 74.
    Reno F, Grazianetti P, Cannas M. Effects of mechanical compression on hypertrophic scars: prostaglandin E2 release. Burns 2001; 27: 205–214CrossRefGoogle Scholar
  75. 75.
    Ahn ST, Mustoe TA, Monafo WW. Topical silicone gel: a new treatment for hypertrophic scars. Surgery 1989; 106: 781–787PubMedGoogle Scholar
  76. 76.
    Rusciani L, Rossi G, Bono R. Use of cryotherapy in the treatment of keloids. J Dermatol Surg Oncol 1993; 19: 529–534PubMedGoogle Scholar
  77. 77.
    Zouboulis CC, Blume U, Buttner P, et al. Outcomes of cryosurgery in keloids and hypertrophic sars. Arch Dermatol 1993; 129: 1146–1151PubMedCrossRefGoogle Scholar
  78. 78.
    Layton AM, Yip J, Cunliffe WI. A comparison of intralesional triamcinolone and cryosurgery in the treatment of acne keloids. Br J Dermatol 1994; 130: 498–501PubMedCrossRefGoogle Scholar
  79. 79.
    Lahiri A, Tsiliboti D, Gaze NR. Experience with difficult keloids. Br J Plast Surg 2001; 54: 633–635PubMedCrossRefGoogle Scholar
  80. 80.
    Perkins K, Davey RB, Wallis KA. Silicone gel: a new treatment for burn scars and contractures. Burns 1983; 9: 201–204CrossRefGoogle Scholar
  81. 81.
    Mercer DM. Silicone gel in the treatment of keloids scars. Br J Plast Surg 1989; 42: 83–87PubMedGoogle Scholar
  82. 82.
    Abn ST, Monafo WW, Mustoe TA. Topical silicone gel for prevention and treatment of hypertrophic scars. Arch Surg 1991; 126: 499–504CrossRefGoogle Scholar
  83. 83.
    Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1996; 22: 126–130PubMedCrossRefGoogle Scholar
  84. 84.
    Fulton Jr JE. Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloids scars. Dermatol Surg 1995; 21: 947–951PubMedCrossRefGoogle Scholar
  85. 85.
    De Oliveira GV, Nunes TA, Magna LA. Silicone versus nonsilicone gel dressings: a controlled trial. Dermatol Surg 2001; 27: 721–726PubMedCrossRefGoogle Scholar
  86. 86.
    Berman B, Flores F. Comparison of a silicone gel-filled cushion and silicon gel sheeting for the treatment of hypertrophic of keloids scars. Dermatol Surg 1999; 25: 484–486PubMedCrossRefGoogle Scholar
  87. 87.
    Gold MH, Foster TD, Adair MA, et al. Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an office setting. Dermatol Surg 2001; 27: 641–644PubMedCrossRefGoogle Scholar
  88. 88.
    Beranak IT. Silicone gel sheeting for the management of hypertrophic and keloids scars: the mechanism of its action. Dermatol Surg 1997; 23: 401–405CrossRefGoogle Scholar
  89. 89.
    Darzi MA, Chowdri NA, Kaul SK, et al. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg 1992; 45: 374–379PubMedCrossRefGoogle Scholar
  90. 90.
    Griffith BH. The treatment of keloids with triamcinolone acetonide. Plast Reconstr Surg 1966; 38: 202–208PubMedCrossRefGoogle Scholar
  91. 91.
    Griffith BH, Monroe CW, McKinney P. A follow-up study on the treatment of keloids with triamcinolone acetonide. Plast Reconstr Surg 1970; 46: 145–1450PubMedCrossRefGoogle Scholar
  92. 92.
    Chowdri NA, Mattoo MMA, Darzi MA. Keloids and hypertrophic scars: results with intraoperative and serial postoperative corticosteroid injection therapy. Aust N Z J Surg 1999; 69: 655–659PubMedCrossRefGoogle Scholar
  93. 93.
    Kill J. Keloids treated with topical injections of triamcinolone acetonide (Kenalog). Scand J Plast Reconstr Surg 1977; 11: 169–172CrossRefGoogle Scholar
  94. 94.
    Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560–571PubMedCrossRefGoogle Scholar
  95. 95.
    Berman B, FloresF. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997; 37: 755–757PubMedCrossRefGoogle Scholar
  96. 96.
    Conejo-Mir JS, Corbi R. Carbon dioxide laser ablation associated with interferon alfa-2b injection reduces the recurrence of keloids. J Am Acad Dermatol 1998; 39: 1039–1040PubMedCrossRefGoogle Scholar
  97. 97.
    Granstein RD, Rook A, Flotte TJ, et al. A controlled trial of intralesional recorminant interferon-gamma in the treatment of keloidal scarring: Clinical and histologic findings. Arch Dermatol 1990; 126: 1295–1302PubMedCrossRefGoogle Scholar
  98. 98.
    Wong TW, Chiu HC, Yip KM. Intralesional interferon alfa-2b has no effect in the treatment of keloids. Br J Dermatol 1994; 130: 683–685PubMedCrossRefGoogle Scholar
  99. 99.
    Al-Khawajah MM. Failure of interferon alpha-2b in the treatment of mature keloids. Int J Dermatol 1996; 35: 515–517PubMedCrossRefGoogle Scholar
  100. 100.
    Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 1999; 25: 224–232PubMedCrossRefGoogle Scholar
  101. 101.
    Uppal RS, Khan U, Kakar S, et al. The effects of a single dose of 5-fluorouracil on keloids scars: a clinical trial of tirred wound irrigation after extralesional excision. Plast Reconstr Surg 2001; 108: 1218–1224PubMedCrossRefGoogle Scholar
  102. 102.
    Abergel RP, Dwyer RM, Meeker CA, et al. Laser treatment of keloids: a clinical trial and an in vitro study with Nd: YAG laser. Lasers Surg Med 1984; 4: 291–295PubMedCrossRefGoogle Scholar
  103. 103.
    Apfelberg DB, Maser MR, White DN, et al. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9: 382–388PubMedCrossRefGoogle Scholar
  104. 104.
    Apfelberg DB, Maser MR, Lash H, et al. Preliminary results of argon and carbon dioxide laser treatment of keloids scars. Lasers Surg Med 1984; 4: 283–290PubMedCrossRefGoogle Scholar
  105. 105.
    Henderson DL, Cromwell TA, Mes LG. Argon and carbon dioxide laser treatment of hypertrophic and keloids scars. Lasers Surg Med 1984; 3: 271–277PubMedCrossRefGoogle Scholar
  106. 106.
    Hulsbergen-Henning JP, Roskam Y, van Gemert MJ. Treatment of keloids and hypertrophic scars with an argon laser. Lasers Surg Med 1986; 6: 72–77PubMedCrossRefGoogle Scholar
  107. 107.
    Sherman R, Rosenfeld H. Experieoce with the Nd: YAG laser in the treatment of keloids scars. Ann Plast Surg 1988; 21: 231–235PubMedCrossRefGoogle Scholar
  108. 108.
    Stern JC, Locente FE. Carbon dioxide laser excision of earlobe keloids: a prospective study and critical analysis of existing data. Arch Otolaryngol Head Neck Surg 1989; 115: 1107–1111PubMedCrossRefGoogle Scholar
  109. 109.
    Alster TS. Improvement of erythematous and hypertrophic scars by the 585nm pulsed dye laser. Ann Plast Surg 1994; 32: 186–190PubMedCrossRefGoogle Scholar
  110. 110.
    Alster TS, Kurban AK, Grove GL, et al. Alteration of argon laser-indoced scars by the pulsed dye laser. Lasers Surg Med 1993; 13: 368–373PubMedCrossRefGoogle Scholar
  111. 111.
    Alster TS, Lewis AB, Rosenbach A. Laser scar revision: comparison of C02 laser vaporization with and without simultaneous pulsed dye laser. Dermatol Surg 1998; 24: 1299–1302PubMedCrossRefGoogle Scholar
  112. 112.
    Alster TS, McMeekin TO. Improvement of facial acne scars by the 585nm flashlamp-pumped pulsed dye laser. J Am Acad Dermatol 1996; 35: 79–81PubMedCrossRefGoogle Scholar
  113. 113.
    Alster TS, Nanni CA. Pulsed dye laser treatment of hypertrophic burn scars. Plast Reconstr Surg 1998; 102: 2190–2195PubMedCrossRefGoogle Scholar
  114. 114.
    Alster TS, Williams CM. Treatment of keloids sternotomy scars with the 585nm flashlamp-pumped pulsed dye laser. Laocet 1995; 345: 1198–1200Google Scholar
  115. 115.
    Manuskiatti W, Fitzpatrick RE, Goldman MP. Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. J Am Acad Dermatol 2001; 45: 557–565PubMedCrossRefGoogle Scholar
  116. 116.
    Dierickx C, Goldman MP, Fitzpatrick RE. Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast Reconstr Surg 1995; 95: 84–90PubMedCrossRefGoogle Scholar
  117. 117.
    Lupton JR, Alster TS. Laser scar revision. Dermatol Clin 2002; 20: 55–65PubMedCrossRefGoogle Scholar
  118. 118.
    Alster TS. Laser scar revision: comparison of pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg 2002; 29: 25–29CrossRefGoogle Scholar
  119. 119.
    Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002; 138: 1149–1155PubMedCrossRefGoogle Scholar
  120. 120.
    Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg 2001; 27: 23–27PubMedCrossRefGoogle Scholar
  121. 121.
    Mikulec AA, Hanasono MM, Lum J, et al. Effect of tamoxifen on transforming growth factor beta1 prodoction by keloids and fetal fibroblasts. Arch Facial Plast Surg 2001; 3: 111–114PubMedCrossRefGoogle Scholar
  122. 122.
    Chau D, Mancoll JS, Lee S, et al. Tamoxifen down regulates TGF-beta production in keloid fibroblasts. Ann Plast Surg 1998; 40: 490–493PubMedCrossRefGoogle Scholar
  123. 123.
    Panabiere-Castaings MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol 1988; 14: 1275–1276PubMedGoogle Scholar
  124. 124.
    Kim A, DeCarlo J, Cohen C, et al. Are keloids really “gli-loids”?: high-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001; 45: 707–711PubMedCrossRefGoogle Scholar
  125. 125.
    Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47: S209–S11PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.The Washington Institute of Dermatologic Laser SurgeryWashington, DCUSA

Personalised recommendations